Identity
ADP399 is an experimental branched dimer developed from ADP355.
K562 and MCF-7 cell growth assays.
Peptide library
ADP399
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
Greater activity than ADP355 in selected cell assays does not establish a superior clinical medicine. Dimer identity, exposure, tissue selectivity and toxicity require independent characterization.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
K562 and MCF-7 cell growth assays.
What the sources found
The dimer had greater activity than ADP355 in the tested cellular assays. This is not a clinical comparison.
K562 and MCF-7 cell growth assays.
Regulatory scope
No jurisdiction-specific marketing authorization has been verified in this snapshot; study publication is not regulatory approval.
What remains unknown
These findings do not establish human efficacy, long-term safety, or equivalence to products sold under this name. This is a focused source snapshot, not an exhaustive clinical review.
How it works
ADP399 is an experimental branched dimer developed from ADP355.
Read the study-specific findings and limitations in Medical. Mechanistic activity does not establish a treatment benefit.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Reported adverse effects
- The cited evidence does not establish comprehensive human adverse-event rates.
Contraindications
- A complete clinical contraindication profile has not been established in this review.
Preclinical research
The catalog primarily cites laboratory or animal research. Human benefit, a safe dose and long-term risks cannot be inferred from those findings.
Sources used for this snapshot
Claim-by-claim evidence
Findings
The dimer had greater activity than ADP355 in the tested cellular assays. This is not a clinical comparison.
K562 and MCF-7 cell growth assays.
References
Otvos et al. Development of second generation peptides modulating cellular adiponectin receptor responses. 2014.
PMID: 25368867
Catalog review date: Sep 6, 2026. This date alone does not establish independent clinical review.